Transcranial Direct Current Stimulation for Post-stroke Gait Rehab

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Recruiting
CT.gov ID
NCT03666533
Collaborator
(none)
50
1
2
48.6
1

Study Details

Study Description

Brief Summary

Stroke affects upwards of 800,000 Americans every year and has an enormous impact on the well-being of the American Veteran population with 6,000 new stroke admissions every year. Many of these stroke survivors are living with walking disabilities. Gait problems result in inability to function independently, high risk of falls and poor quality of life. Unfortunately, current gait rehabilitation treatments are limited and many stroke survivors do not achieve full recovery. Therefore, it is critical to develop new approaches to enhance gait rehabilitation methods. The investigators propose to evaluate a brain stimulation treatment called transcranial Direct Current Stimulation (tDCS) that can be added to physical therapy. tDCS has been applied for arm rehabilitation after stroke with positive results, but gait-related investigations are lacking. The investigators will test whether simultaneous tDCS and gait training produces greater improvement in walking abilities than gait training alone. Adjunct tDCS therapy may improve outcomes, and reduce cost of both rehabilitation and post-stroke care.

Condition or Disease Intervention/Treatment Phase
  • Other: Active transcranial Direct Current Stimulation
  • Other: Sham transcranial Direct Current Stimulation
Phase 2

Detailed Description

Current rehabilitation methods fail to restore normal gait for many stroke survivors leading to dependence on others, recurrent falls, limitations in community ambulation and poor quality of life. The main objective of this study is to test both efficacy and neurophysiological mechanisms of a novel approach to treat persistent gait deficits after stroke with a combination of simultaneous non-invasive brain stimulation with transcranial Direct Current Stimulation (tDCS) and gait training. The investigators will enroll chronic stroke subjects (>6 months) with gait deficits. Subjects will be randomized to 10 sessions of either active tDCS+gait training or sham tDCS+gait training. Gait training will be accomplished in the treadmill-based Virtual Reality environment targeting longer single limb stance with the paretic limb. The primary outcome measure will be both gait speed and single limb stance duration. Other outcome measures will assess various components of gait-related functional domains. The study will also characterize neuroplastic brain changes in response to bihemispheric tDCS combined with gait training based on corticospinal excitability using motor evoked potentials and functional connectivity using resting state functional Magnetic Resonance Imaging (rs-fMRI).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
transcranial Direct Current Stimulationtranscranial Direct Current Stimulation
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transcranial Direct Current Stimulation for Post-stroke Gait Rehab
Actual Study Start Date :
Sep 13, 2018
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active tDCS

active tDCS plus gait training

Other: Active transcranial Direct Current Stimulation
Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
Other Names:
  • tDCS
  • Sham Comparator: Sham tDCS

    sham tDCS plus gait training

    Other: Sham transcranial Direct Current Stimulation
    Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
    Other Names:
  • Sham tDCS
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Gait Speed from baseline [at 1-4 days after completion of 10-session intervention protocol]

      Gait speed will be calculated based on Ten Meter Walk Test

    Other Outcome Measures

    1. Change in Motor Evoked Potentials from baseline [at 1-4 days after completion of 10-session intervention protocol]

      Measure of corticospinal excitability

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Medically and psychologically stable and at least 6 months after first ever unilateral stroke

    • Cognition sufficiently intact to give valid informed consent to participate

    • FMLE score >15; and ability to actively dorsiflex the paretic ankle in synergy (FMLE item II Flexor synergy-ankle dorsiflexion score 1).

    • Sufficient endurance to participate in the study

    Exclusion Criteria:
    • Activity tolerance is insufficient to complete treadmill training

    • Inability to produce a trace contraction of ankle dorsiflexors in synergy

    • Normal ankle dorsiflexion/knee flexion on FMLE standing items (FMLE item IV score=4)

    • Stroke affecting both sides

    • Contraindications for rTMS according to the most recent TMS-use guidelines

    • Contraindications for MRI

    • Inability to understand English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Louis Stokes VA Medical Center, Cleveland, OH Cleveland Ohio United States 44106

    Sponsors and Collaborators

    • VA Office of Research and Development

    Investigators

    • Principal Investigator: Svetlana Pundik, MD, Louis Stokes VA Medical Center, Cleveland, OH

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    VA Office of Research and Development
    ClinicalTrials.gov Identifier:
    NCT03666533
    Other Study ID Numbers:
    • N2620-R
    • 15036-H19
    First Posted:
    Sep 11, 2018
    Last Update Posted:
    Jan 14, 2022
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by VA Office of Research and Development
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 14, 2022